Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Tasquinimod |
Synonyms | |
Therapy Description |
Tasquinimod is a small molecule that exerts anti-tumor activity through both stimulation of immune response and inhibition of tumor angiogenesis (PMID: 24162378, PMID: 30431595). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Tasquinimod | ABR-215050|TASQ | Tasquinimod is a small molecule that exerts anti-tumor activity through both stimulation of immune response and inhibition of tumor angiogenesis (PMID: 24162378, PMID: 30431595). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04405167 | Phase I | Tasquinimod Dexamethasone + Ixazomib + Lenalidomide + Tasquinimod | Tasquinimod for the Treatment of Relapsed or Refractory Myeloma | Recruiting | USA | 0 |
NCT02396368 | Phase I | Tasquinimod Radium Ra 223 dichloride | A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer | Withdrawn | USA | 0 |
NCT02159950 | Phase II | Sipuleucel-T Tasquinimod | Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | Completed | USA | 0 |
NCT06327100 | Phase II | Tasquinimod Ruxolitinib + Tasquinimod | Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF) | Recruiting | USA | 0 |
NCT01513733 | Phase I | Tasquinimod Cabazitaxel | The CATCH Prostate Cancer Trial Cabazitaxel And Tasquinimod in Men With Prostate Cancer | Completed | USA | 0 |